The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells-Reference-Cited by-同舟云学术

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells

Published:2010-11-03 Issue:2 Volume:129 Page:387-400
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Brünner-Kubath Caroline,Shabbir Waheed,Saferding Victoria,Wagner Renate,Singer Christian F.,Valent Peter,Berger Walter,Marian Brigitte,Zielinski Christoph C.,Grusch Michael,Grunt Thomas W.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-010-1232-1.pdf

Reference56 articles.

1. Yarden Y, Baselga J, Miles D (2004) Molecular approach to breast cancer treatment. Semin Oncol 31(Suppl 10):6–13

2. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516

3. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

4. Ocaña A, Amir E (2009) Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treat Rev 35:685–691

5. Rabindran SK, Discafani CM, Rosfjord EC et al (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64:3958–3965

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bibliometric and visualization analysis of research trends and hotspots on targeted therapy for breast cancer from 2003 to 2022;Frontiers in Oncology;2024-06-04

2. Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article;Global Medical Genetics;2023-05-23

3. Pharmacological Inhibition of Lipid Import and Transport Proteins in Ovarian Cancer;Cancers;2022-12-05

4. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs;Cancers;2022-09-19

5. The Anti-Proliferative Effect of PI3K/mTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models;Cancers;2022-01-13